Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with papilloma virus infection.
The follow-up is presented for 13 patients with cervical intraepithelial neoplasia (CIN) grade II-III and vulvar intraepithelial neoplasia (VIN) grade III associated with papilloma virus infection, treated with human fibroblast interferon. Treatment consisted of 2-3 X 10(6) IU interferon per day injected intra- and peri-lesionally for five days per week for 2-3 weeks, with or without a cream topically applied at the dose of 1.2 X 10(6) IU/day X five days. Among the 13 patients with CIN and VIN, 7 complete (54%) and 2 partial regressions were observed. The duration of response appeared to be between 2 and 14 months. Fever, chills and fatigue were the tolerable side-effects. Our results indicate that treatment with interferon is active against CIN and VIN associated with papilloma virus infection.
D000328:Adult; D000818:Animals; D003218:Condylomata Acuminata / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007370:Interferon Type I / Q000276:immunology*; D008875:Middle Aged; D027383:Papillomaviridae; D014412:Tumor Virus Infections / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014846:Vulvar Neoplasms / Q000628:therapy*
D007370:Interferon Type I